KCNN4 and Parkinson disease: We hypothesized that KCa3.1 involved in microgliosis-induced SNpc neuronal loss and demonstrated that both genetic deletion and pharmacological blockade of KCa3.1 reduced dopaminergic (DA) neuron loss and improved the locomotor ability via reducing microgliosis-mediated neuroinflammatory cytokine production in PD.